Cue Biopharma, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Cue Biopharma, Inc. payments for repurchase of common stock for the quarter ending 2023-12-31 was $0.00.
- Cue Biopharma, Inc. payments for repurchase of common stock for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Cue Biopharma, Inc. payments for repurchase of common stock for the quarter ending 2023-06-30 was $0.00.
- Cue Biopharma, Inc. payments for repurchase of common stock for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Cue Biopharma, Inc. payments for repurchase of common stock for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Cue Biopharma, Inc. payments for repurchase of common stock for fiscal 2022 was $200.00K, a 73.34% decline from fiscal 2021.
- Cue Biopharma, Inc. payments for repurchase of common stock for fiscal 2021 was $750.13K, a 176.75% increase from fiscal 2020.
- Cue Biopharma, Inc. payments for repurchase of common stock for fiscal 2020 was $271.05K, a 197.77% increase from fiscal 2019.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $9.00K derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $9.00K derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $200.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $383.13K derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $856.13K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $191.00K 10-Q · filed 2023-05-09 | $856.13K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $183.13K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $750.13K 10-K · filed 2023-03-21 |
| 2021-09-30 | $482.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $727.05K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $280.05K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $85.00K 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $160.05K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $271.05K 10-K · filed 2022-03-16 |
| 2020-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | |
| 2019-12-31 | $91.03K 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |